Evaluation of a Diabetes Vaccine in Newly Diagnosed Diabetics
|ClinicalTrials.gov Identifier: NCT00057499|
Recruitment Status : Completed
First Posted : April 4, 2003
Last Update Posted : February 8, 2017
Insulin dependent diabetes mellitus (also called type 1 diabetes mellitus or T1DM) is caused by the destruction of insulin-producing cells in the pancreas. People with T1DM do not produce enough insulin, which is necessary for proper regulation of blood sugar levels.
T1DM is an autoimmune disease. An autoimmune disease is a disease in which the body's immune system attacks the body itself. In addition to regulating blood sugar, insulin may have the ability to protect cells in the pancreas from attack by the immune system. This study will evaluate whether an insulin-based vaccine can protect cells from autoimmune destruction.
Study hypothesis: IFA-enhanced human insulin B-chain vaccination will lead to the arrest or slowing of the ongoing autoimmunity, and this will result in an appreciable difference in functioning B cell mass compared to the placebo treated group by the end of the study.
|Condition or disease||Intervention/treatment||Phase|
|Insulin-dependent Diabetes Mellitus Diabetes Mellitus||Biological: IBC-VS01 Biological: IBC-VS01 placebo||Phase 1|
The vaccine in this study, IBC-VSO1, is a synthetic, metabolically inactive form of insulin designed to prevent pancreatic beta-cell destruction. It does not cause fluctuations in blood sugar. This study will evaluate whether the vaccine protects against autoimmune attack at the onset of T1DM, before pancreas function has deteriorated. This experimental treatment must occur early because 60% to 85% of beta-cells are already destroyed by the time of T1DM diagnosis. If beta-cell destruction can be halted, a prolonged remission period after diagnosis may occur, with a subsequent delay in diabetes-related complications.
Participants must have been diagnosed with T1DM for no more than 3 months at the time of enrollment in this study. Participants will be randomly assigned to either a vaccine group or a control group. Participants in the vaccine group will receive one injection of IBC-VS01; participants in the control group will receive a placebo. Participants will then be monitored for 2 years. Participants will have ten follow-up visits, which will include blood tests for immunological and genetic analysis. Throughout the study, metabolic tests will also be performed to measure the remaining capacity of self insulin production of the body.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Autoantigen Vaccination in Human Type 1 Newly Diagnosed Diabetes Mellitus|
|Study Start Date :||March 2003|
|Primary Completion Date :||March 2007|
|Study Completion Date :||March 2007|
Experimental: IBC-VS01 vaccine
IBC-VS01 vaccine is administered twice.
Placebo Comparator: Control Group
IBC-VS01 placebo is administered twice
Biological: IBC-VS01 placebo
- Clinical endpoints including adverse events, local reactions, routine physical exams, insulin dose, and laboratory tests [ Time Frame: Throughout study ]
- C-peptide levels in response to mixed meal tolerance test [ Time Frame: Throughout study ]
- HbA1c, GAD65Ab, IAA, IA2Ab, GAD65Ab isotypes [ Time Frame: Throughout study ]
- CD4- and CD8- Va24JaQ+ [ Time Frame: Throughout study ]
- T cells' secretion of IL-4 and Interferon (IFN)-gamma [ Time Frame: Throughout study ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00057499
|United States, Massachusetts|
|Boston, Massachusetts, United States, 02115|
|Joslin Diabetes Center|
|Boston, Massachusetts, United States, 02215|
|Principal Investigator:||Tihamer Orban, MD||Joslin Diabetes Center|